Leap Therapeutics Q4 EPS $(0.46) Beats $(0.55) Estimate, Cash Balance of $70.6M
Portfolio Pulse from Benzinga Newsdesk
Leap Therapeutics (NASDAQ:LPTX) reported Q4 earnings with losses of $(0.46) per share, surpassing the analyst consensus estimate of $(0.55). This represents a 58.18% improvement over the previous year's losses of $(1.10) per share. The company also reported a cash balance of $70.6M.
March 18, 2024 | 11:19 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leap Therapeutics reported a significant improvement in Q4 losses and beat analyst estimates, with a healthy cash balance of $70.6M.
Beating the analyst estimates by a significant margin and showing a substantial year-over-year improvement in losses could lead to increased investor confidence and potentially drive the stock price up in the short term. The reported healthy cash balance further supports the company's financial stability, adding to the positive outlook.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100